Biocryst Pharmaceuticals Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development
Published: Dec 18, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
Help employers find you! Check out all the jobs and post your resume.